KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Change in Account Payables data on record, last reported at -$29.0 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 824.15% year-over-year to -$29.0 million; the TTM value through Dec 2025 reached $39.9 million, up 298.53%, while the annual FY2025 figure was $39.9 million, 298.53% up from the prior year.
  • Change in Account Payables reached -$29.0 million in Q4 2025 per JAZZ's latest filing, down from $62.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $62.4 million in Q3 2025 and bottomed at -$32.0 million in Q2 2021.
  • Average Change in Account Payables over 5 years is $3.8 million, with a median of -$1.6 million recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 20493.66% in 2022, then tumbled 1042.52% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $37.9 million in 2021, then plummeted by 140.72% to -$15.4 million in 2022, then surged by 47.43% to -$8.1 million in 2023, then skyrocketed by 61.31% to -$3.1 million in 2024, then crashed by 824.15% to -$29.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$29.0 million in Q4 2025, $62.4 million in Q3 2025, and -$12.7 million in Q2 2025.